// App-Quantinova.ai

POS0194 (2021) : ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OR ADALIMUMAB: A POST HOC ANALYSIS OF EXCEED

Researchers

Presenter

  • G. S. Kaeley

Principal Investigators

  • G. Schett

  • P. G. Conaghan

  • D. Mcgonagle

  • F. Behrens

  • P. Goupille

  • C. Gaillez

  • X. Meng

Medical Centers

  • University of Florida, Department of Medicine, Division of Rheumatology and Clinical Immunology, Jacksonville, United States of America

  • Friedrich Alexander University Erlangen-Nuremberg and Universitaetsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Leeds Teaching Hospitals, National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, United Kingdom

  • Goethe University, Rheumatology and Fraunhofer Institute Translational Medicine and Pharmacology ITMP, Frankfurt, Germany

  • University Hospital of Tours, University of Tours, Department of Rheumatology, Tours, France

  • Novartis Pharma AG, Global Medical Affairs, Basel, Switzerland

  • Novartis Pharmaceuticals Corporation, US HEOR, East Hanover, United States of America

  • Novartis Pharmaceuticals Corporation, US HEOR, East Hanover, United States of America

  • Intermountain Healthcare Medical Group, Rheumatology, Salt Lake City, United States of America

Locations

  • United States

  • Germany

  • United Kingdom

  • France

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02745080

Sponsors

  • Novartis Pharma

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved